Ritter Pharmaceuticals (NASDAQ:RTTR) Trading Down 16.7%

Ritter Pharmaceuticals Inc (NASDAQ:RTTR)’s stock price dropped 16.7% during trading on Thursday . The company traded as low as $0.20 and last traded at $0.20, approximately 568,300 shares were traded during mid-day trading. A decline of 3% from the average daily volume of 583,543 shares. The stock had previously closed at $0.24.

A number of research firms recently commented on RTTR. ValuEngine raised shares of Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, September 30th. Zacks Investment Research cut shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 17th.

The business’s 50 day moving average is $0.28 and its 200 day moving average is $0.74. The stock has a market capitalization of $2.59 million, a PE ratio of -0.05 and a beta of 1.12.

Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.18.

Ritter Pharmaceuticals Company Profile (NASDAQ:RTTR)

Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.

Featured Article: How to Trade Using Analysts Ratings

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.